Efficacy of 177-Lutetium DOTATATE Peptide Receptor Radionuclide Therapy in patients with metastatic NENs and carcinoid syndrome refractory to somatostatin analogues

被引：0

作者：

Ratnayake, G. M. ^{[1
]}

Koffas, A. ^{[1
]}

Theocharopoulos, I ^{[1
]}

Hayes, A. ^{[1
]}

Navalkissoor, S. ^{[1
]}

Gnanasegaran, G. ^{[1
]}

Quigley, A. M. ^{[1
]}

Khoo, B. ^{[1
]}

Mandair, D. ^{[1
]}

Grossman, A. ^{[1
]}

Caplin, M. ^{[1
]}

Alsadik, S. ^{[1
]}

Clark, R. ^{[1
]}

Toumpanakis, C. ^{[1
]}

机构：

[1] Royal Free Hosp, ENETS Ctr Excellence, London, England

来源：

JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷

关键词：

carcinoid syndrome; prrt;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

H24

引用

页码：157 / 157

页数：1

共 50 条

[1] Efficacy of Lutetium-177 DOTA Octreotate Peptide Receptor Radionuclide Therapy in Patients with Advanced Neuroendocrine Tumours and Carcinoid Syndrome Refractory to Somatostatin Analogues
Koffas, A.
Popat, R.
Dimitriou, G.
Quigley, A. M.
Navalkissoor, S.
Caplin, M.
Toumpanakis, C.
NEUROENDOCRINOLOGY, 2016, 103 : 81 - 81
[2] Effect of Lutetium-177 Dota Octreotate Peptide Receptor Radionuclide Therapy in Patients With Advanced Neuroendocrine Tumors and Carcinoid Syndrome Refractory to Somatostatin Analogues
Koffas, Apostolos
Popat, Rickin
Demetriou, George
Quigley, Ann-Marie
Navalkissoor, Shaunak
Caplin, Martyn
Toumpanakis, Christos
GASTROENTEROLOGY, 2016, 150 (04) : S208 - S208
[3] Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
Zandee, Wouter T.
Brabander, Tessa
Blazevic, Anela
Minczeles, Noemie S.
Feelders, Richard A.
de Herder, Wouter W.
Hofland, Johannes
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (09): : E3665 - E3672
[4] Preliminary dosimetric study with 177-Lutetium Peptide Receptor Radionuclide Therapy for Pediatric Patients with neuroendocrine tumors
Cassano, B.
Genovese, E.
Polito, C.
Longo, M.
Donatiello, S.
Napolitano, A.
Insero, T.
Valeri, S.
Pizzoferro, M.
Serra, A.
Garganese, M. C.
Cannata, V.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S87 - S87
[5] Lutetium-177 Dotatate Peptide Receptor Radionuclide Therapy in metastatic pheochromocytoma and paraganglioma: Experience in our center
Negre, M.
Guardeno, R.
Biarnes, J.
Recasens, M.
Rubio, A.
JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 210 - 210
[6] Peptide Receptor Radionuclide Therapy with Lu-177 DOTATATE in patients with somatostatin receptor positive tumours
Kamaleshwaran, K.
Sudhakar, N.
Paulvannan, S.
Vysakh, M.
Shinto, A.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S722 - S722
[7] Lutetium-177 Dotatate peptide receptor radionuclide therapy outcomes for neuroendocrine tumours
AlHilali, M.
Carberry, J.
Challis, A.
Atherton, P.
RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1095 - S1096
[8] Peptide Receptor Radionuclide Therapy with Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
Zandee, W.
Blazevic, A.
Brabander, T.
Kam, B. L.
Teunissen, J. J.
Feelders, R. A.
Hofland, J.
de Herder, W. W.
NEUROENDOCRINOLOGY, 2019, 108 : 235 - 235
[9] Peptide Receptor Radionuclide Therapy (177Lutetium DOTATATE) as a Treatment Modality for Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL)
Armeni, E.
Sullivan, L.
Quigley, A. M.
Navalkissoor, S.
Caplin, M.
Hayes, A. R.
Grossman, A. B.
Khoo, B.
Toumpanakis, C.
NEUROENDOCRINOLOGY, 2019, 108 : 197 - 197
[10] Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors
Abou Jokh Casas, E.
Pombo Pasin, M. D.
Pubul Nunez, V.
Garrido Pumar, M.
Blanco Freire, M. N.
Cabezas, J.
Cameselle, J.
Berrios, M.
Argibay, S.
Ruibal Morell, A.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S597 - S598

← 1 2 3 4 5 →